Prescribed by medical professionals and guided by registered nurses from our secure, HIPAA-compliant telemedicine platform, KetaMD provides safe, effective, and potentially life-changing at-home ketamine treatments for those who are suffering from depression, anxiety, and other mental health challenges.

Our Story

KetaMD was founded by Warren Gumpel and Zappy Zapolin, two pioneers in the psychedelic industry.

For the last decade, Warren and Zappy have dedicated their lives to help those suffering from debilitating mental heath issues find relief through psychedelic medicines.

Having personally experienced the healing benefits of ketamine, they sought out to bring this innovative treatment to those greatly in need through The Ketamine Fund, a non-profit devoted to help veterans and others fighting life-threatening mental health disorders.

Since its founding in 2019, The Ketamine Fund and its founders have donated approximately 500 free and subsidized treatments to veterans and their families.

When the Covid-19 pandemic hit in 2020, access to the in-person ketamine clinics serving this community evaporated. Zappy and Warren knew they had to find another way.

They partnered with Chief Experience Officer and bestselling mindfulness author Kaia Roman, and from there KetaMD was born.

Warren Gumple
Warren Gumpel

Co-Founder & CEO

Warren is a leading advocate in the ketamine space who has spent the last five years working as an operator, consultant, and marketer. Warren has guided existing ketamine clinics, IV clinics, and rehab centers across the U.S. to integrate best ketamine practices. Warren is also an accomplished TV and film producer.
Zappy Zapolin
Zappy Zapolin

Co-Founder & Executive Chairman

Zappy has worked extensively in the ketamine space for the last five years, co- founding and operating The Ketamine Fund (501c3) and personally supporting hundreds of patients during treatments. Zappy is also an award-winning filmmaker; his latest film, Lamar Odom: Reborn, follows the psychedelic intervention he facilitated for the superstar.

Fast forward to present day, our mission at KetaMD is to expand access and awareness to this revolutionary treatment to as many as possible at a time when mental health issues are devastating people across the nation and the world.

With a dedicated team of doctors, nurses, and professionals who are equally devoted to helping those suffering, we aim to make ketamine treatment mainstream in our healthcare system.

We’re glad you’re here to join us on this journey, to find your own personal healing path and to spread the word to so many who could benefit from this revolutionary treatment.

The KetaMD Leadership Team

The KetaMD team is made up of real people whose lives have been changed in a significant way by ketamine treatments, and we are passionate about making these treatments available to everyone who can benefit from them.

The core values of KetaMD orbit around a centralized mission of healing and an unyielding belief in the life-transforming power of ketamine treatment. We are doctors, nurses, mothers, fathers, brothers, and sisters who are deeply dedicated to sharing this profound treatment with a world so desperately ready for change.

Dr. Daniel Kang
Dr. Daniel Kang

Chief Medical Officer, KetaMD

Dr. Daniel Kang is a Los Angeles native and a UC Berkeley grad. Upon graduating, he worked at a non-profit community health center where his data research and collaboration with the state of California helped to increase resources for underserved communities. He attended medical school at Albert Einstein College of Medicine, and completed his residency in Anesthesiology at Brigham and Women’s Hospital, an institution of Harvard Medical School.

In pursuit of providing anesthetic care across all ages, he continued his training as a pediatric anesthesiology fellow at Children’s Hospital of Los Angeles. Dr. Kang is passionate about improving access to quality care and creating efficiencies through the use of technology. As such, he has various publications on optimization of patient experience, automation of preoperative triage, and identifying risk factors for patient safety.

As CMO of KetaMD, he is committed to creating the gold standard for at-home ketamine treatment with an emphasis on patient experience and best-in-class integration. His mission is not only to deliver ketamine safely, but to create lasting change and improvement in people’s lives by sharing tools and teachings for success.

Dr. Edward Pearson
Dr. Edward Pearson

Medical Director, KMD Medical Group

Dr. Edward Pearson received his undergraduate training in Microbiology and Chemistry from the University of Florida, and his medical degree with an Academic Excellence Award from the University of South Florida, College of Medicine. He completed his internship from UC Davis in Sacramento in 2000. He became licensed and immediately began practicing as a primary care physician.

Displeased with what he saw in conventional medicine, after completing his internship and a short time in a Physical Medicine & Rehabilitation residency, Dr. Pearson set out on his own to find the education that would teach him how to truly heal people and prevent the epidemics of chronic illness plaguing humanity.

Dr. Pearson has now become a worldwide expert in the field of truly integrated health care, he was certified by the American Board of Holistic Medicine in 2005 and 2011 and receives ongoing training from the best educators in the world, including the Institute of Functional Medicine and others.

Kaia Roman
Kaia Roman

Co-Founder, Chief Experience Officer

Kaia is a certified mindfulness instructor and the bestselling author of The Joy Plan, recently featured on the TODAY show. Inspired by her personal healing experiences with ketamine and psychedelic medicine, Kaia is merging 20 years of brand experience work in Silicon Valley (for clients such as Google, Twilio, and Doctor on Demand) with her neuroscience and mindfulness training to bring the profound healing capabilities of these treatments to as many people as possible.
Jamie Rollins
Jamie Rollins BSN, RN

Head of Nursing & Clinical Operations

Jamie has been a Registered Nurse in the Hospice & Psychiatric setting for the majority of her 18 years in the field. In 2018 she launched TrueHealth Consulting, a cannabis consulting company, where she assisted physicians & nurses entering the cannabis business world and guided patients in the right direction for medical cannabis needs and services.

She opened a local cannabis clinic and assisted in opening one of the first dispensaries in her Florida home town. Jamie is a dynamic leader and national speaker in the Psychedelic Nursing & Cannabis Nursing industry, where she inspires other nurses to share their gifts with the world and become entrepreneurs. She also developed the ‘first of its kind’ training for ketamine telehealth nurses here at KetaMD.

Her time spent working with two of the most vulnerable patient populations is what now fuels her passion to ease human suffering, and what drives her to develop innovative ways to help patients find the healing they need.

An Expert Medical

Advisory Team

KetaMD's expert medical team is led by several of the world’s leading depression researchers and practitioners.

Together, we have created a safe and convenient medical protocol to help those whose mental health is suffering — all while never having to leave the comfort of their homes.

Dr. Roger McIntyre
Dr. Roger McIntyre

CEO, Braxia Scientific

Dr. Roger McIntyre is the chairman and chief executive officer of Braxia Scientific. Dr. McIntyre is the world’s top-ranked depression researcher and has almost 25 years of providing care and conducting research, along with drug discovery and development, for persons with depression and related disorders. He is a professor of psychiatry and pharmacology at the University of Toronto and Head of the Mood Disorders, Psychopharmacology Unit at the University Health Network in Toronto. 

Dr. McIntyre serves as the Executive Director of the Brain and Cognition Discovery Foundation in Toronto and is the Director and Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance.  He was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019, 2020 and 2021 as one of “The World’s Most Influential Scientific Minds”. Dr. McIntyre has authored/co-authored more than 785 publications, and has edited and/or co-edited several textbooks on mood disorders.  He is involved in multiple research endeavors which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. 

Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders.

Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level.

Dr. Joshua Rosenblat
Dr. Joshua Rosenblat

Chief Scientific and Medical Officer, Braxia Scientific

Dr. Joshua Rosenblat is the medical director and researcher at the Canadian Rapid Treatment Centre of Excellence (CRTCE). Dr. Rosenblat is also a clinician-scientist at the Mood Disorders Psychopharmacology Unit (MDPU) at Toronto Western Hospital and at the University of Toronto. 

Dr. Rosenblat has treated hundreds of patients with ketamine infusions for treatment-resistant depression, bipolar disorder, suicidality and PTSD.  He also continues to conduct numerous research studies to better understand how the use of ketamine may be optimized in psychiatry to allow for rapid and sustained symptom relief and full functional recovery. 

Dr. Rosenblat’s primary clinical focus is treatment-resistant unipolar and bipolar depression and his research focus is conducting clinical trials to identify and evaluate novel psychopharmacological interventions for mood disorders that may substantially improve patient outcomes. He has authored and co-authored over a hundred journal articles and textbook chapters in prestigious journals, such as the New England Journal of Medicine, JAMA Psychiatry, the American Journal of Psychiatry and the Journal of Clinical Psychiatry. He has received numerous local, national and international grants and awards for his research in mood disorders.

Dr. Rosenblat is also actively involved in teaching medical students and residents locally and nationally.

Dr. Sanjiv Chopra
Dr. Sanjiv Chopra

Professor of Medicine, Harvard Medical School

Dr. Sanjiv Chopra is a Professor of Medicine at Harvard Medical School and a Senior Consultant in Hepatology at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. Like his brother Deepak Chopra, Dr. Chopra is a bestselling author and sought-after motivational speaker. He has scores of publications to his credit, including seven books that have been translated into multiple languages.

Dr. Chopra is also the Editor-in-Chief of the Hepatology Section of UpToDate, the most widely used electronic textbook in the world (subscribed to by an estimated 950,000 physicians worldwide).

Dr. Yousif A-Rahim
Dr. Yousif A-Rahim

Harvard Medical School Faculty and Physician Executive

Dr. Yousif A-Rahim is the Chief Medical Officer for Covenant Physician Partners, a physician services company partnering with more than 1,800 leading providers across the country to grow thriving practices. As a lecturer in Medicine at Harvard Medical School, Dr. A- Rahim has authored many articles published in medical journals and delivered presentations to fellow physicians around the world.

Dr. A-Rahim is also a healthcare investor and international healthcare entrepreneur.